Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a Phase 2 clinical-stage biopharmaceutical company focused on personalized oncology through the development of stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor, and its proprietary DRP® companion diagnostic platform. The Allarity news feed highlights how the company advances this program in advanced ovarian cancer and other hard-to-treat malignancies.
News updates commonly cover clinical trial milestones, such as enrollment progress and new Phase 2 data in platinum-resistant or platinum-ineligible ovarian cancer, including Kaplan–Meier analyses of overall survival and durability of response. Releases also report on regulatory developments, notably the FDA Fast Track designation granted to stenoparib for advanced ovarian cancer, and on scientific presentations at meetings like the AACR Special Conference on Ovarian Cancer and Biomarkers & Precision Medicine.
Investors and observers will find coverage of corporate and financial updates, including quarterly results, capital structure actions, and private placement transactions disclosed via Form 8-K. Additional news items describe the expansion of Allarity’s DRP® platform through licensing and laboratory services agreements with EU-based biotechnology partners, patent developments such as Australian acceptance for the stenoparib DRP®, and collaborations with institutions like the Indiana Biosciences Research Institute.
This page aggregates these announcements so readers can follow how Allarity is progressing stenoparib in ovarian cancer, preparing combination studies in recurrent small cell lung cancer, and broadening the use of its DRP® technology across oncology. For ongoing insight into trial data, regulatory interactions, intellectual property, and financing events related to ALLR, this curated news stream provides a centralized view.
On August 26, 2022, Allarity Therapeutics (Nasdaq: ALLR) disclosed receipt of a non-compliance letter from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the quarter ending June 30, 2022. This notification does not immediately affect the company's stock listing but poses a risk of delisting if compliance is not restored. The company has 60 days to submit a plan, and if accepted, may have up to 180 days to file the report. Allarity aims to file the Form 10-Q as soon as possible, maintaining focus on its oncology drug development.
Allarity Therapeutics, Inc. has refocused its oncology pipeline strategy from monotherapy to combination therapies. This shift aims to align with the growing standard of care in oncology, optimize funding opportunities, and enhance commercial prospects. The Board's decision follows feedback from the FDA indicating the need for additional studies on dovitinib's dosing before proceeding to Phase 3 trials. The company plans to initiate a Phase 1b/2 study of stenoparib in combination with dovitinib for ovarian cancer by Q4 2022. Ongoing studies for stenoparib and IXEMPRA will continue as planned.
Allarity Therapeutics, Inc. announced the appointment of David A. Roth, M.D., as a new board member, effective July 7, 2022. Interim CEO James G. Cullem and co-founder Thomas Jensen also joined the board. Dr. Roth brings over 25 years of experience in oncology drug development, enhancing Allarity's strategy in personalized cancer care through its Drug Response Predictor (DRP®) companion diagnostics. The DRP® platform has shown significant predictive ability in clinical outcomes across multiple studies, underscoring Allarity's commitment to improving therapeutic response rates for cancer patients.
Allarity Therapeutics has appointed James G. Cullem, J.D., as interim CEO and Joan Y. Brown, CPA, as interim CFO, following the resignation of former CEO Steve R. Carchedi and CFO Jens Knudsen. The leadership transition aims to prepare the company for future growth. Cullem, with over 20 years in life sciences, has been with Allarity since 2014, focusing on the acquisition of key oncology assets. Brown brings extensive financial reporting experience, contributing to Allarity's Nasdaq listing. The board anticipates naming permanent executives in the first half of 2023.
Allarity Therapeutics has announced the appointment of Dr. Roberto Pili to its Scientific Advisory Board. With extensive expertise in renal cancers and personalized medicine, Dr. Pili will contribute to advancing Allarity's clinical programs. The company specializes in oncology therapeutics and uses its proprietary Drug Response Predictor (DRP) companion diagnostics to enhance treatment efficacy. Dr. Pili's experience includes conducting clinical trials and publishing over 200 peer-reviewed articles. Allarity aims to improve cancer treatment outcomes through innovative therapies guided by individualized patient diagnostics.
Allarity Therapeutics reported their Q1 2022 financial results, showing a net loss of $3.1 million, unchanged from Q1 2021. Their cash reserves declined to $14.5 million from $19.6 million in the previous quarter. R&D expenses remained flat at $1.3 million year over year, while G&A expenses rose significantly to $3.0 million from $1.2 million. The company recorded a notable $14.0 million impairment of intangible assets, compared to none in the prior year. Allarity continues to advance its pipeline for personalized cancer therapies using its DRP® companion diagnostics.
Allarity Therapeutics (NASDAQ: ALLR) corrected a typographical error in its press release dated May 16, 2022. The company stated that the debt cancellation amount was incorrectly reported as "$971 million" instead of "$971 thousand." This debt cancellation exempts Allarity from future financial obligations related to the LiPlaCis® program, allowing for potential milestone payments of up to $3.5 million. The company is focused on developing personalized cancer treatments using its Drug Response Predictor (DRP®) companion diagnostic technology.
Allarity Therapeutics reported financial results for Q4 and full year 2021, highlighting significant achievements including a successful Nasdaq listing under symbol ALLR and a record investment of $20 million. The company advanced its cancer therapeutics pipeline and announced a forbearance agreement to address compliance issues with Nasdaq. Notably, R&D expenses surged to $14.2 million, leading to a net loss of $26.6 million for 2021. Positive developments include a Type C meeting with the FDA on dovitinib and milestone payments from partnerships. Cash reserves increased to $19.6 million.
Allarity Therapeutics, Inc. (Nasdaq: ALLR) announced it is not in compliance with Nasdaq Listing Rule 5250(c)(1), due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The notification does not immediately affect the listing of the Company's common stock. Allarity has 60 days to submit a compliance plan, with a potential extension of up to 180 days if accepted. The Company aims to file its Form 10-K by June 19, 2022, to eliminate the need for a formal compliance plan.
Allarity Therapeutics has requested a Type C meeting with the FDA to discuss the next steps for dovitinib, after the agency issued Refusal to File letters for its NDA and PMA applications. The Company aims to clarify the requirements for resubmission and anticipates a new clinical trial may be necessary. Allarity plans to provide updates on the meeting outcomes and further advancements for dovitinib and its DRP-Dovitinib companion diagnostic by the end of Q3 2022. CEO Steve Carchedi remains confident in dovitinib's potential as a treatment for cancer patients.
FAQ
What is the current stock price of Allarity (ALLR)?
What is the market cap of Allarity (ALLR)?
